Suzhou Runxin Biotechnology

Suzhou Runxin Biotechnology, also known as NeuPharma, is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small-molecule anti-cancer therapies. Founded in 2009, the company utilizes its proprietary drug discovery platform to advance a pipeline of targeted treatments, including its lead candidate RX108, a first-in-class Na+/K+-ATPase inhibitor currently in Phase 2 trials for glioblastoma and hepatocellular carcinoma. Another key asset, RX208 (uplarafenib), is a BRAF V600E inhibitor licensed to Henlius for development in various solid tumors. NeuPharma maintains a strong focus on oncology and has established strategic partnerships with global and domestic pharmaceutical companies to accelerate the commercialization of its pipeline.